1、Pietris J, Tong JY, Selva D. Primary dacryocystorhinostomy for acute 
dacryocystitis: a systematic review[ J]. Semin Ophthalmol, 2024: 1-9. DOI:10.1080/08820538.2024.2344714.Pietris J, Tong JY, Selva D. Primary dacryocystorhinostomy for acute 
dacryocystitis: a systematic review[ J]. Semin Ophthalmol, 2024: 1-9. DOI:10.1080/08820538.2024.2344714.
							  
                                  
                                      
								  2、Avdagic E, Phelps PO. Nasolacrimal duct obstruction as an important 
cause of Epiphora[ J]. Dis Mon, 2020, 66(10): 101043. DOI:10.1016/
j.disamonth.2020.101043.Avdagic E, Phelps PO. Nasolacrimal duct obstruction as an important 
cause of Epiphora[ J]. Dis Mon, 2020, 66(10): 101043. DOI:10.1016/
j.disamonth.2020.101043.
							  
                                  
                                      
								  3、Chong KK , Abdulla HA A , Ali MJ. An update on endoscopic 
mechanical and powered dacryocystorhinostomy in acute dacryocystitis 
and lacrimal abscess[ J]. Ann Anat, 2020, 227: 151408. DOI:10.1016/
j.aanat.2019.07.009.Chong KK , Abdulla HA A , Ali MJ. An update on endoscopic 
mechanical and powered dacryocystorhinostomy in acute dacryocystitis 
and lacrimal abscess[ J]. Ann Anat, 2020, 227: 151408. DOI:10.1016/
j.aanat.2019.07.009.
							  
                                  
                                      
								  4、Ali MJ, Joshi SD, Naik MN, et al. Clinical profile and management 
outcome of acute dacryocystitis: two decades of experience in a tertiary 
eye care center[ J]. Semin Ophthalmol, 2015, 30(2): 118-123. DOI:10.
3109/08820538.2013.833269.Ali MJ, Joshi SD, Naik MN, et al. Clinical profile and management 
outcome of acute dacryocystitis: two decades of experience in a tertiary 
eye care center[ J]. Semin Ophthalmol, 2015, 30(2): 118-123. DOI:10.
3109/08820538.2013.833269.
							  
                                  
                                      
								  5、中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗
指南编写审定专家组. 中国慢性淋巴细胞白血病/小淋巴细胞
淋巴瘤的诊断与治疗指南(2022年版) [EB/OL]. (2022-09-21)
[2025-09-15]. http://www.szsdsrmyy.com/
 Expert group for the compilation and approval of the guidelines for 
the diagnosis and treatment of chronic lymphocytic leukemia/small 
lymphocytic lymphoma in China Chinese guidelines for the diagnosis 
and treatment of chronic lymphocytic leukemia/small lymphocytic 
lymphoma (2022 Edition) [EB/OL]. (2022-09-21)[2025-09-15]. 
http://www.szsdsrmyy.com/Expert group for the compilation and approval of the guidelines for 
the diagnosis and treatment of chronic lymphocytic leukemia/small 
lymphocytic lymphoma in China Chinese guidelines for the diagnosis 
and treatment of chronic lymphocytic leukemia/small lymphocytic 
lymphoma (2022 Edition) [EB/OL]. (2022-09-21)[2025-09-15]. 
http://www.szsdsrmyy.com/
							  
                                  
                                      
								  6、Diop F, Moia R, Favini C, et al. Biological and clinical implications of 
BIRC3 mutations in chronic lymphocytic leukemia[ J]. Haematologica, 
2020, 105(2): 448-456. DOI:10.3324/haematol.2019.219550.Diop F, Moia R, Favini C, et al. Biological and clinical implications of 
BIRC3 mutations in chronic lymphocytic leukemia[ J]. Haematologica, 
2020, 105(2): 448-456. DOI:10.3324/haematol.2019.219550.
							  
                                  
                                      
								  7、L e w i s R I , Vo m Ste i n A F, Ha l l e k M . Ta r ge t i ng t h e t u m o r 
microenvironment for treating double-refractory chronic lymphocytic 
leukemia[ J]. Blood, 2024, 144(6): 601-614. DOI:10.1182/
blood.2023022861.L e w i s R I , Vo m Ste i n A F, Ha l l e k M . Ta r ge t i ng t h e t u m o r 
microenvironment for treating double-refractory chronic lymphocytic 
leukemia[ J]. Blood, 2024, 144(6): 601-614. DOI:10.1182/
blood.2023022861.
							  
                                  
                                      
								  8、Ranaweera Arachchige T, Mendiburu C, Martin A, et al. Clinical and 
biological characterization of involvement of nasal-associated lymphoid 
tissues in chronic lymphocytic leukemia[ J]. Am J Hematol, 2024, 
99(8): 1628-1631. DOI:10.1002/ajh.27357.Ranaweera Arachchige T, Mendiburu C, Martin A, et al. Clinical and 
biological characterization of involvement of nasal-associated lymphoid 
tissues in chronic lymphocytic leukemia[ J]. Am J Hematol, 2024, 
99(8): 1628-1631. DOI:10.1002/ajh.27357.
							  
                                  
                                      
								  9、Wierda WG, Brown J, Abramson JS, et al. Chronic lymphocytic 
leukemia/small lymphocytic lymphoma, version 2.2024, NCCN 
clinical practice guidelines in oncology[ J]. J Natl Compr Canc Netw, 
2024, 22(3): 175-204. DOI:10.6004/jnccn.2024.0018.Wierda WG, Brown J, Abramson JS, et al. Chronic lymphocytic 
leukemia/small lymphocytic lymphoma, version 2.2024, NCCN 
clinical practice guidelines in oncology[ J]. J Natl Compr Canc Netw, 
2024, 22(3): 175-204. DOI:10.6004/jnccn.2024.0018.
							  
                                  
                                      
								  10、Wirostko WJ, Garcia GH, Cory S, et al. Acute dacryocystitis as a 
presenting sign of pediatric leukemia[ J]. Am J Ophthalmol, 1999, 
127(6): 734-736. DOI:10.1016/s0002-9394(99)00023-9.Wirostko WJ, Garcia GH, Cory S, et al. Acute dacryocystitis as a 
presenting sign of pediatric leukemia[ J]. Am J Ophthalmol, 1999, 
127(6): 734-736. DOI:10.1016/s0002-9394(99)00023-9.
							  
                                  
                                      
								  11、Mishra DK, Ali MJ, Bhargava A, et al. Acute dacryocystitis as a 
presenting sign of chronic lymphocytic leukaemia[ J]. Clin Exp 
Ophthalmol, 2016, 44(1): 67-69. DOI:10.1111/ceo.12579.Mishra DK, Ali MJ, Bhargava A, et al. Acute dacryocystitis as a 
presenting sign of chronic lymphocytic leukaemia[ J]. Clin Exp 
Ophthalmol, 2016, 44(1): 67-69. DOI:10.1111/ceo.12579.
							  
                                  
                                      
								  12、Karesh JW, Perman KI, Rodrigues MM. Dacryocystitis associated with 
malignant lymphoma of the lacrimal sac[ J]. Ophthalmology, 1993, 
100(5): 669-673. DOI:10.1016/s0161-6420(93)31590-3.Karesh JW, Perman KI, Rodrigues MM. Dacryocystitis associated with 
malignant lymphoma of the lacrimal sac[ J]. Ophthalmology, 1993, 
100(5): 669-673. DOI:10.1016/s0161-6420(93)31590-3.
							  
                                  
                                      
								  13、Knop E, Knop N. Lacrimal drainage-associated lymphoid tissue 
(LDALT): a part of the human mucosal immune system[ J]. Invest 
Ophthalmol Vis Sci, 2001, 42(3): 566-574.Knop E, Knop N. Lacrimal drainage-associated lymphoid tissue 
(LDALT): a part of the human mucosal immune system[ J]. Invest 
Ophthalmol Vis Sci, 2001, 42(3): 566-574.
							  
                                  
                                      
								  14、Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between 
tumor cells and their microenvironment[ J]. Blood, 2006, 107(5): 
1761-1767. DOI:10.1182/blood-2005-08-3182.Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between 
tumor cells and their microenvironment[ J]. Blood, 2006, 107(5): 
1761-1767. DOI:10.1182/blood-2005-08-3182.
							  
                                  
                                      
								  15、Sallusto%20F%2C%20Lenig%20D%2C%20F%C3%B6rster%20R%20%2C%20et%20al.%20Two%20subsets%20of%20memory%20T%20%0Alymphocytes%20with%20distinct%20homing%20potentials%20and%20effector%20functions%5B%20J%5D.%20%0ANature%2C%201999%2C%20401(6754)%3A%20708-712.%20DOI%3A10.1038%2F44385.Sallusto%20F%2C%20Lenig%20D%2C%20F%C3%B6rster%20R%20%2C%20et%20al.%20Two%20subsets%20of%20memory%20T%20%0Alymphocytes%20with%20distinct%20homing%20potentials%20and%20effector%20functions%5B%20J%5D.%20%0ANature%2C%201999%2C%20401(6754)%3A%20708-712.%20DOI%3A10.1038%2F44385.
							  
                                  
                                      
								  16、Li Y, Shi Y, McCaw L, et al. Microenvironmental interleukin-6 
suppresses toll-like receptor signaling in human leukemia cells through 
miR-17/19A[ J]. Blood, 2015, 126(6): 766-778. DOI:10.1182/
blood-2014-12-618678.Li Y, Shi Y, McCaw L, et al. Microenvironmental interleukin-6 
suppresses toll-like receptor signaling in human leukemia cells through 
miR-17/19A[ J]. Blood, 2015, 126(6): 766-778. DOI:10.1182/
blood-2014-12-618678.
							  
                                  
                                      
								  17、Díez P, Juanes-Velasco P, García-Vaquero ML, et al. Tonic signaling of 
the B-cell antigen-specific receptor is a common functional hallmark 
in chronic lymphocytic leukemia cell phosphoproteomes at early 
disease stages[ J]. Mol Oncol, 2025. DOI:10.1002/1878-0261.70032. 
DOI:10.1002/1878-0261.70032.Díez P, Juanes-Velasco P, García-Vaquero ML, et al. Tonic signaling of 
the B-cell antigen-specific receptor is a common functional hallmark 
in chronic lymphocytic leukemia cell phosphoproteomes at early 
disease stages[ J]. Mol Oncol, 2025. DOI:10.1002/1878-0261.70032. 
DOI:10.1002/1878-0261.70032.
							  
                                  
                                      
								  18、Liang W, Fan Y, Liu Y, et al. ROS/pH dual-sensitive emodinchlorambucil co-loaded micelles enhance anti-tumor effect through 
combining oxidative damage and chemotherapy[ J]. Int J Pharm, 2023, 
647: 123537. DOI:10.1016/j.ijpharm.2023.123537.Liang W, Fan Y, Liu Y, et al. ROS/pH dual-sensitive emodinchlorambucil co-loaded micelles enhance anti-tumor effect through 
combining oxidative damage and chemotherapy[ J]. Int J Pharm, 2023, 
647: 123537. DOI:10.1016/j.ijpharm.2023.123537.
							  
                                  
                                      
								  19、Al-Adl M, Youssef MM, El-Sebaie A, et al. The role of polymorphic 
cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia 
(B-CLL) incidence and outcome among Egyptian patients[ J]. Oncol 
Res, 2024, 32(4): 785-797. DOI:10.32604/or.2024.047021.Al-Adl M, Youssef MM, El-Sebaie A, et al. The role of polymorphic 
cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia 
(B-CLL) incidence and outcome among Egyptian patients[ J]. Oncol 
Res, 2024, 32(4): 785-797. DOI:10.32604/or.2024.047021.
							  
                                  
                                      
								  20、Griggio V, Vitale C, Todaro M, et al. HIF-1α is over-expressed in 
leukemic cells from TP53-disrupted patients and is a promising 
therapeutic target in chronic lymphocytic leukemia[ J]. Haematologica, 
2020, 105(4): 1042-1054. DOI:10.3324/haematol.2019.217430.Griggio V, Vitale C, Todaro M, et al. HIF-1α is over-expressed in 
leukemic cells from TP53-disrupted patients and is a promising 
therapeutic target in chronic lymphocytic leukemia[ J]. Haematologica, 
2020, 105(4): 1042-1054. DOI:10.3324/haematol.2019.217430.
							  
                                  
                                      
								  21、Song M, Graubard BI, Loftfield E, et al. White blood cell count, 
neutrophil-to-lymphocyte ratio, and incident cancer in the UK 
biobank[ J]. Cancer Epidemiol Biomarkers Prev, 2024, 33(6): 821-829. 
DOI:10.1158/1055-9965.EPI-23-1145.Song M, Graubard BI, Loftfield E, et al. White blood cell count, 
neutrophil-to-lymphocyte ratio, and incident cancer in the UK 
biobank[ J]. Cancer Epidemiol Biomarkers Prev, 2024, 33(6): 821-829. 
DOI:10.1158/1055-9965.EPI-23-1145.
							  
                                  
                                      
								  22、Robbertz AS, Weiss DM, Awan FT, et al. Identifying risk factors for 
depression and anxiety symptoms in patients with chronic lymphocytic 
leukemia[ J]. Support Care Cancer, 2020, 28(4): 1799-1807. 
DOI:10.1007/s00520-019-04991-y.Robbertz AS, Weiss DM, Awan FT, et al. Identifying risk factors for 
depression and anxiety symptoms in patients with chronic lymphocytic 
leukemia[ J]. Support Care Cancer, 2020, 28(4): 1799-1807. 
DOI:10.1007/s00520-019-04991-y.